APSR2026-312

 
Late-Breaking
Submitted
Oral Presentation
AO27-003
 
 
https://storage.unitedwebnetwork.com/files/1285/1218001-46903-AO27-003_ESCAPE_TB2_APSR2026_440853.pptx
Format: PPTX Only
 
Format: PDF Only
06. Tuberculosis
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Jia-Yih Feng * Taipei Veterans General Hospital Department of Chest Medicine Taipei Taiwan
Shin-Jung Lee - Kaohsiung Veterans General Hospital Division of Infectious Diseases Kaohsiung Taiwan
Chin-Chung Shu - National Taiwan University Hospital Department of Internal Medicine Taipei Taiwan
Shu-Min Lin - Chang Gung Memorial Hospital Department of chest medicine Taipei Taiwan
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Jia-Yih
Feng
peterofeng@gmail.com
+886921050484
41-50
Taiwan
Original Research
Short-course, 4-month regimen (2HREZ/2HR) for non-severe, low-risk, active pulmonary tuberculosis: a multicenter, randomized controlled trial in Taiwan
Maximum 25 words
Abstract Content
While 4-month regimens containing rifapentine and moxifloxacin are now recommended for drug-susceptible tuberculosis (DS-TB), limited global availability and high pill burdens remain significant barriers. This study evaluated whether a shortened 4-month course of standard first-line treatment—isoniazid (H), rifampin (R), ethambutol (E), and pyrazinamide (Z) via fixed-dose combinations (FDC)—is effective for patients with mild disease and low recurrence risk.
We conducted a multi-center, prospective, randomized clinical trial across four centers in Taiwan. Eligible participants included adults with non-severe, drug-susceptible pulmonary TB at low risk for recurrence. Patients were randomized to receive a standard 6-month regimen containing 2HREZ/4HR(E) or a short-course 4-month regimen of 2HREZ/2HR(E) in a 1:1 ratio. The sputum smear and culture for TB were followed at 8-week, 16-week, 24-week, as well as 6 and 12 months after treatment completion. The primary efficacy endpoints were the rate of sputum culture conversion at weeks 8, 16, and 24, and the rate of TB recurrence 12 months after treatment completion.
From January 2024 to December 2025, a total of 144 patients were enrolled for analysis, including 74 randomized to the 4-month regimen and 70 randomized to the 6-month regimen. Their mean age was 68.1 +/- 14.3 years and 83 (57.6%) were male. At baseline, 113 (78.5%) were smear negative and 76 (55.5%) were TB culture positive. The culture negative rate at 8-week, 16-week and 24-week were 96.6%, 100%, and 100% in the 4-month group, and 94.7%, 100%, and 100% in the 6-month group. Among these patients, 29 (20.1%) remained under treatment, 91 (63.2%) completed the treatment, 6 (4.2%) were transferred out. There were 5 deaths during the study period, all attributed to non-TB causes. 80 patients finished the 12-month follow-up and none reported recurrence of active tuberculosis both in either the 4-month or 6-month treatment groups. Treatment discontinuation rate was comparable between the two groups of patients (31.1% vs. 30.0%, p=0.56)
In patients with non-severe, low-risk of recurrence, drug-susceptible active TB, a shortened 4-month HREZ regimen using standard fixed-dose combinations demonstrated comparable efficacy and safety to the 6-month standard of care. This regimen provides a viable, cost-effective alternative to longer standard treatments.
 
 
 
 
 
No
Yes
https://storage.unitedwebnetwork.com/files/1285/1218001-37089-Tables_375711.png
JPG or JPEG or PNG format ONLY
Pulmonary tuberculosis, short course, relapse, non-severe
maximum 3 keywords and no abbreviations, separated by commas
 
370